FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a method of treating CBS deficiency in an individual, comprising determining a metabolic rate of severity of disease or disease progression in an individual, where the metabolic indicator of disease severity or disease progression is total homocysteine (tHcy), and administering to an individual a therapeutically effective amount of a pharmaceutical composition containing a drug substance containing an isolated cystathionine protein-β-synthase (CBS), and where the individual is a patient with a genetically non-heritable disease associated with high levels of tHcy, or a patient with a non-heritable disease associated with CBS deficiency.
EFFECT: invention provides a method of treating individuals with CBS deficiency and/or high tHcy levels, in which HCU has not been diagnosed or its genetic predisposition has not been detected.
2 cl, 4 dwg, 10 tbl, 8 ex
| Title |
Year |
Author |
Number |
| PEGYLATED CYSTATHIONINE-BETA-SYNTHASE FOR ENZYME THERAPY FOR TREATMENT OF HOMOCYSTINURIA |
2020 |
- Bublil, Erets
- Glavin, Frenk
- Sellos-Mura, Marsiya
- Majtan, Tomas
- Kraus, Yan P.
- Vanner, Rendi
- Kausevich, Orkhan
|
RU2839909C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS |
2015 |
- Andre Paskal
- Bleri Mate
- Sulas Karolina
- Vagtmann Nikolaj
|
RU2721271C2 |
| COMBINATION OF MONOCLONAL ANTIBODIES OF OX40 AGONIST AND 4-1BB AGONIST FOR CANCER TREATMENT |
2017 |
- Long, Hua
- Thall, Aron David
|
RU2748949C2 |
| IL-4/IL-13 PATHWAY INHIBITORS FOR HIGHER EFFICACY IN TREATING MALIGNANT NEOPLASMS |
2020 |
- Liot, Caroline
- Kuhnert, Frank
|
RU2836467C2 |
| COMBINATION OF PD-1 ANTAGONIST, VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER |
2020 |
- Ozawa, Yoichi
- Funahashi, Yasuhiro
- Kato, Yu
|
RU2838452C1 |
| METHOD FOR INCREASING THERAPEUTIC EFFICACY OF FEXAPOTIDE TRIFLUTATE IN LUTS TREATMENT |
2020 |
|
RU2825641C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER |
2016 |
- Matsui, Junji
- Aktan, Gursel
- Karantza, Vassiliki
- Yuan, Ruirong
- Funahashi, Yasuhiro
- Berrak, Erhan
|
RU2737216C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION |
2019 |
- Conner, Edward R.
- Riley, Brigit E.
- Rouy, Didier
|
RU2799048C2 |
| METHOD OF TREATING LOWER URINARY TRACT SYMPTOMS USING FEXAPOTIDE TRIFLUTATE |
2020 |
|
RU2839726C2 |
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS |
2012 |
- Sharma Manodzh K.
- Narasimkhan Chakravarti Nachu
- Gergich Kevin Dzhejms
- Kang Soonmo Piter
|
RU2563346C2 |
